Header Logo

Connection

Shama Khan to Humans

Back to Details
This is a "connection" page, showing publications Shama Khan has written about Humans.
Shama Khan
Connection Strength
0,540
Humans
  1. Structure-based identification of novel inhibitors targeting the enoyl-ACP reductase enzyme of Acinetobacter baumannii. Sci Rep. 2023 12 04; 13(1):21331.
    View in: PubMed
    Score: 0,068
  2. Targeting ebola virus VP40 protein through novel inhibitors: exploring the structural and dynamic perspectives on molecular landscapes. J Mol Model. 2021 Jan 25; 27(2):49.
    View in: PubMed
    Score: 0,055
  3. Structure-based identification of potential SARS-CoV-2 main protease inhibitors. J Biomol Struct Dyn. 2022 05; 40(8):3595-3608.
    View in: PubMed
    Score: 0,055
  4. Selective Covalent Inhibition of "Allosteric Cys121" Distort the Binding of PTP1B Enzyme: A Novel Therapeutic Approach for Cancer Treatment. Cell Biochem Biophys. 2019 Sep; 77(3):203-211.
    View in: PubMed
    Score: 0,050
  5. Reversible versus irreversible inhibition modes of ERK2: a comparative analysis for ERK2 protein kinase in cancer therapy. Future Med Chem. 2018 05 01; 10(9):1003-1015.
    View in: PubMed
    Score: 0,046
  6. Thymoquinone, artemisinin, and thymol attenuate proliferation of lung cancer cells as Sphingosine kinase 1 inhibitors. Biomed Pharmacother. 2024 Aug; 177:117123.
    View in: PubMed
    Score: 0,018
  7. Exploring therapeutic potential of Rutin by investigating its cyclin-dependent kinase 6 inhibitory activity and binding affinity. Int J Biol Macromol. 2024 Apr; 264(Pt 2):130624.
    View in: PubMed
    Score: 0,017
  8. Investigating the role of thymol as a promising inhibitor of pyruvate dehydrogenase kinase 3 for targeted cancer therapy. Int J Biol Macromol. 2024 Feb; 259(Pt 2):129314.
    View in: PubMed
    Score: 0,017
  9. Investigating potential of cholic acid, syringic acid, and mangiferin as cancer therapeutics through sphingosine kinase 1 inhibition. Int J Biol Macromol. 2023 Dec 31; 253(Pt 5):127036.
    View in: PubMed
    Score: 0,017
  10. Naringenin as a potential inhibitor of human cyclin-dependent kinase 6: Molecular and structural insights into anti-cancer therapeutics. Int J Biol Macromol. 2022 Jul 31; 213:944-954.
    View in: PubMed
    Score: 0,015
  11. Myricetin inhibits breast and lung cancer cells proliferation via inhibiting MARK4. J Cell Biochem. 2022 02; 123(2):359-374.
    View in: PubMed
    Score: 0,015
  12. Investigating single amino acid substitutions in PIM1 kinase: A structural genomics approach. PLoS One. 2021; 16(10):e0258929.
    View in: PubMed
    Score: 0,015
  13. MAP/Microtubule Affinity Regulating Kinase 4 Inhibitory Potential of Irisin: A New Therapeutic Strategy to Combat Cancer and Alzheimer's Disease. Int J Mol Sci. 2021 Oct 12; 22(20).
    View in: PubMed
    Score: 0,015
  14. Impact of single amino acid substitution on the structure and function of TANK-binding kinase-1. J Cell Biochem. 2021 10; 122(10):1475-1490.
    View in: PubMed
    Score: 0,014
  15. Structure-based investigation of MARK4 inhibitory potential of Naringenin for therapeutic management of cancer and neurodegenerative diseases. J Cell Biochem. 2021 10; 122(10):1445-1459.
    View in: PubMed
    Score: 0,014
  16. ABBV-744 as a potential inhibitor of SARS-CoV-2 main protease enzyme against COVID-19. Sci Rep. 2021 01 08; 11(1):234.
    View in: PubMed
    Score: 0,014
  17. Identification of Potential Inhibitors of Calcium/Calmodulin-Dependent Protein Kinase IV from Bioactive Phytoconstituents. Oxid Med Cell Longev. 2020; 2020:2094635.
    View in: PubMed
    Score: 0,013
  18. Inhibition of ergosterol synthesis in Candida albicans by novel eugenol tosylate congeners targeting sterol 14a-demethylase (CYP51) enzyme. Arch Microbiol. 2020 May; 202(4):711-726.
    View in: PubMed
    Score: 0,013
  19. Tracing Potential Covalent Inhibitors of an E3 Ubiquitin Ligase through Target-Focused Modelling. Molecules. 2019 Aug 28; 24(17).
    View in: PubMed
    Score: 0,013
  20. Distinguishing the optimal binding mechanism of an E3 ubiquitin ligase: Covalent versus noncovalent inhibition. J Cell Biochem. 2019 08; 120(8):12859-12869.
    View in: PubMed
    Score: 0,012
  21. Exploring the Structural Mechanism of Covalently Bound E3 Ubiquitin Ligase: Catalytic or Allosteric Inhibition? Protein J. 2018 12; 37(6):500-509.
    View in: PubMed
    Score: 0,012
  22. An update on the discovery and development of selective heat shock protein inhibitors as anti-cancer therapy. Expert Opin Drug Discov. 2018 10; 13(10):903-918.
    View in: PubMed
    Score: 0,012
  23. Covalent Inhibition in Drug Discovery: Filling the Void in Literature. Curr Top Med Chem. 2018; 18(13):1135-1145.
    View in: PubMed
    Score: 0,011
  24. PKR-inhibitor binds efficiently with human microtubule affinity-regulating kinase 4. J Mol Graph Model. 2015 Nov; 62:245-252.
    View in: PubMed
    Score: 0,010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.